Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas
Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas
复制标题
DOI：
10.1007/s12094-010-0539-z
复制
发表时间：
2010-07-01
影响因子：
3.4
通讯作者：
Hitt, Ricardo
中科院分区：
文献类型：
--
作者：
Homet Moreno, Blanca;Garralda Cabanas, Elena;Hitt, Ricardo
肉瘤是一种罕见的恶性肿瘤，代表了50多种不同的肿瘤类型。手术仍然是治疗局部疾病的主要手段。蒽环类和异环磷酰胺为基础的化疗是晚期疾病的一种选择;然而，晚期软组织肉瘤的有效治疗仍然是一个挑战。对癌症遗传性质的理解的进展导致了肉瘤新治疗方案的开发。苹果酸舒尼替尼是一种口服多靶点酪氨酸激酶抑制剂，具有抗血管生成特性，在伊马替尼难治性GIST治疗中具有良好的活性，但在任一软组织肉瘤中，舒尼替尼的经验正在不同的临床试验中开发。在这篇综述中，我们提供了这种小分子靶点在非GIST肉瘤中的经验。
Sarcomas are uncommon malignancies that represent more than 50 different tumor types. Surgery remains the mainstay of treating localised disease. Anthracycline and ifosfamide-based chemotherapy is an option for advanced disease; however, effective treatment of advanced soft tissue sarcoma remains a challenge. Advances in understanding the genetic nature of cancer have led to the development of new treatment options for sarcoma. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor with antiangiogenic properties and promising activity in the treatment of GIST refractory to imatinib, however in either soft tissue sarcoma, experience with sunitinib is under development in different clinical trials. In this review we offer the experience with this small molecular target in non-GIST sarcomas.